Abstract:To identify an active inhibitor against the non‐structural protein 3 (nsP3) macrodomain of chikungunya virus (CHIKV), we screened the natural compound libraries from the ZINC database using docking, and molecular dynamics (MD) simulations. The screened compounds were tested for their binding with CHIKV nsP3 protein using microscale thermophoresis binding and thermal shift assay techniques. The shortlisted compounds were authenticated by investigating their effect in the chikungunya virus culture system, where arrest of CHIKV replication was confirmed by a plaque assay and real‐time qRT‐PCR. Discovering an alternative therapy with a long‐lasting effect on symptoms caused by chikungunya virus (CHIKV) infection is prompted by the lack of a vaccine and the absence of safe, effective and non‐toxic medications. One potential strategy is synthesizing or identifying small compounds that can specifically target the active site of an essential enzyme and prevent virus replication. Previous site‐directed mutagenesis studies have demonstrated the crucial role of the macrodomain, which is a part of non‐structural protein 3 (nsP3), in virus replication. Exploiting this fact, the macrodomain can be targeted to discover a natural substance that can inhibit its function and thereby impede virus replication. With this aim, the present study focused on potential CHIKV nsP3 macrodomain (nsP3MD) inhibitors through in silico, in vitro and cell‐based methods. Through virtual screening of the natural compound library, nine nsP3MD inhibitors were initially identified. Molecular dynamics (MD) simulations were employed to evaluate these nine compounds based on the stability of their ligand–receptor complexes and energy parameters. Target analysis and ADMET (i.e. absorption, distribution, metabolism, excretion and toxicity) prediction of the selected compounds revealed their drug‐like characteristics. Subsequent in vitro investigation allowed us to narrow the selection down to one compound, N‐[2‐(5‐methoxy‐1H‐indol‐3‐yl) ethyl]‐2‐oxo‐1,2‐dihydroquinoline‐4‐carboxamide, which exhibited potent inhibition of CHIKV growth. This molecule effectively inhibited CHIKV replication in the stable embryonal rhabdomyosarcoma cell line capable of producing CHIKV. Our findings demonstrate that the selected compound possesses substantial anti‐CHIKV nsP3MD activity both in vitro and in vivo. This work provides a promising molecule for further preclinical studies to develop a potential drug against the CHIKV.

Repurposed drugs in combinations exert additive anti-chikungunya virus activity: an in-vitro study

Repurposing efavirenz, the HIV antiretroviral drug for Chikungunya virus infection

In silico identification and in vitro antiviral validation of potential inhibitors against Chikungunya virus

Cell Culture and Molecular Docking Analysis to Determine the Antiviral Activity of Folklore Medicinal Plants Against Chikungunya Virus

Viral methyltransferase inhibitors: berbamine, venetoclax, and ponatinib as efficacious antivirals against Chikungunya virus

In silico identification of natural antiviral compounds as a potential inhibitor of chikungunya virus non-structural protein 3 macrodomain

Repurposing of approved antivirals against dengue virus serotypes: an in silico and in vitro mechanistic study

New highly selective antivirals for Chikungunya Virus identified from the screening of a drug-like compound library

Antivirals against the Chikungunya Virus

In silico identification of chikungunya virus replication inhibitor validated using biochemical and cell‐based approaches

Identification of Therapeutic Drugs Against COVID-19 Through Computational Investigation on Drug Repurposing and Structural Modification

In silico drug repurposing for the identification of potential candidate molecules against arboviruses infection

Synthesis and Anti-Chikungunya Virus (CHIKV) Activity of Novel 1,4-Naphthoquinone Sulfonamide and Sulfonate Ester Derivatives

Structure–activity relationship study of arbidol derivatives as inhibitors of chikungunya virus replication

Synergistic and Antagonistic Drug Combinations against SARS-CoV-2

The Antifungal Itraconazole Is a Potent Inhibitor of Chikungunya Virus Replication

Compounds from Natural Products Candidates to Drug for Chikungunya Virus Infection: A Systematic Review

Exploring the antiviral activities of the FDA-approved drug sulfadoxine and its derivatives against Chikungunya virus

Inhibitor of the non-structural protein 2 protease shows promising efficacy in mouse models of chikungunya

Etravirine Prevents West Nile Virus and Chikungunya Virus Infection Both In Vitro and In Vivo by Inhibiting Viral Replication

CavitOmiX Drug Discovery: Engineering Antivirals with Enhanced Spectrum and Reduced Side Effects for Arboviral Diseases